Gene therapy for bladder cancer

Area of Science:

• Oncology
• Gene Therapy
• Virology

Background:

• Tumor-suppressor genes are crucial for controlling cell growth.
• p53 gene mutations are common in bladder cancer, leading to uncontrolled cell proliferation.
• Adenoviral vectors offer a method for in vivo gene delivery to tumor cells.

Purpose of the Study:

• To evaluate the safety and efficacy of adenovirus-mediated p53 gene transfer in bladder cancer patients.
• To assess the potential of Ad5CMV-P53 vector for inhibiting tumor growth.
• To establish a foundation for future clinical trials integrating gene therapy with standard treatments.

Main Methods:

• Utilizing a replication-defective adenoviral vector (Ad5CMV-P53) carrying wild-type human p53.
• Administering the vector intravesically (directly into the bladder).
• Conducting a phase I clinical trial to assess safety and preliminary efficacy.

Main Results:

• Adenovirus-mediated p53 gene transfer demonstrated in vitro growth inhibition of bladder cancer cells.
• Phase I clinical trial initiation for intravesical administration of Ad5CMV-P53.
• Preliminary data suggests the potential for therapeutic benefit in bladder cancer.

Conclusions:

• Adenovirus-mediated p53 gene transfer is a promising strategy for bladder cancer treatment.
• The Ad5CMV-P53 vector shows potential for therapeutic application in vivo.
• Further clinical trials are warranted to integrate gene therapy for improved bladder cancer outcomes.